Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Chief Commerical Officer | August 05, 2019 | August 07, 2019 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Commercial Officer | May 16, 2025 | June 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date August 05, 2019 · Filed August 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 39,000 |
Ending reported balance
After 2019-08-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-08-05 · Grant · Acquired 35,000 · Balance 35,000 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on August 5, 2020 through August 5, 2023. Row 2 · 2019-08-05 · Grant · Acquired 4,000 · Balance 39,000 F2: Consists of RSUs. The RSUs vest as to 50% on August 5, 2020 and 50% on August 5, 2021. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.48 · Expires 2029-08-05 | Direct | 25,000 |
Reported balance
After 2019-08-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-05 · Grant · Acquired 25,000 · Balance 25,000 F3: The option vests as to 25% of the shares on August 5, 2020 and the remainder vests quarterly thereafter until August 5, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on August 5, 2020 through August 5, 2023.
F2: Consists of RSUs. The RSUs vest as to 50% on August 5, 2020 and 50% on August 5, 2021.
F3: The option vests as to 25% of the shares on August 5, 2020 and the remainder vests quarterly thereafter until August 5, 2023.
X4 Pharmaceuticals, Inc
Report date May 16, 2025 · Filed June 03, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,337 |
Reported balance
After 2025-05-16 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-05-16 · Grant · Acquired 1,032 · Balance 25,337 F1: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2025 Filed May 20, 2025 20:51 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | PurchaseCommon Stock | 1,032 | $2.48 | $2,561.42 |
DisclosureSEC source: 0001628280-25-026864 · wk-form4_1747774254.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,337 F1 · shares: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Read SEC document |
| May 16, 2025 Filed Jun 3, 2025 21:01 UTC Amendment | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,032 | $2.48 | $2,561.42 |
DisclosureSEC source: 0001628280-25-029113 · wk-form4a_1748984454.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,337 F1 · shares: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 3 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,173 F2 · balance_after: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 29,159 | $0.45 | $13,241.10 |
DisclosureSEC source: 0001628280-25-002707 · wk-form4_1738019726.xml · nonDerivative · entry 2 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,123 F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4475 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 74,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-002707 · wk-form4_1738019726.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,282 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome. Read SEC document |
| November 15, 2024 Filed Feb 14, 2025 21:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | PurchaseCommon Stock | 13,404 | $0.34 | $4,597.57 |
DisclosureSEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 2 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,173 F1 · balance_after: The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 11,127 | $0.58 | $6,505.96 |
DisclosureSEC source: 0001628280-24-042544 · wk-form4_1728420266.xml · nonDerivative · entry 2 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,509 F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 34,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042544 · wk-form4_1728420266.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,636 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition. Read SEC document |
| May 17, 2024 Filed Feb 14, 2025 21:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | PurchaseCommon Stock | 21,646 | $0.68 | $14,654.34 |
DisclosureSEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,769 F1 · balance_after: The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 22:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 523,414 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005380 · wk-form4_1708121338.xml · derivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,414 Underlying: Common Stock · 523,414 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:39 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 10,257 | $0.73 | $7,487.61 |
DisclosureSEC source: 0001628280-23-036756 · wk-form4_1699043973.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,690 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 21:00 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 34,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036466 · wk-form4_1698958841.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,947 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:18 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 341,000 | $1.89 Strike: $1.89 | $644,490.00 |
DisclosureSEC source: 0001628280-22-028462 · wf-form4_166759306432055.xml · derivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,000 Underlying: Common Stock · 341,000 shares Expires 2032-11-03 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 23:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $19.48 | $0.00 |
DisclosureSEC source: 0000899243-19-021293 · doc4.xml · derivative · entry 3 Baldry Mark · CIK 0001644137 · Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2029-08-05 F3 · derivative.exercise_date: The option vests as to 25% of the shares on August 5, 2020 and the remainder vests quarterly thereafter until August 5, 2023. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 23:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021293 · doc4.xml · nonDerivative · entry 2 Baldry Mark · CIK 0001644137 · Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 F2 · shares: Consists of RSUs. The RSUs vest as to 50% on August 5, 2020 and 50% on August 5, 2021. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 23:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021293 · doc4.xml · nonDerivative · entry 1 Baldry Mark · CIK 0001644137 · Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on August 5, 2020 through August 5, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.